Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma

被引:1
作者
Ujjani, Chaitra [1 ]
Cheson, Bruce D. [1 ]
机构
[1] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA
关键词
alkylating agent; antimetabolite; chemotherapy; chronic lymphocytic leukemia; non-Hodgkin's lymphoma; treanda; MULTICENTER PHASE-II; INDOLENT B-CELL; MANTLE CELL; PLUS RITUXIMAB; REFRACTORY INDOLENT; TRIAL; TOXICITY; BENDAMUSTINE/MITOXANTRONE/RITUXIMAB; CHEMOTHERAPY; FLUDARABINE;
D O I
10.1586/ERA.10.116
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bendamustine (Treanda (R); Pharmachemie BV, The Netherlands for Cephalon, Inc., PA, USA) is a unique cytotoxic agent with both alkylating and antimetabolite properties. A growing body of evidence demonstrates its efficacy in a number of hematologic malignancies, and as such, it has been US FDA approved for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma that has not responded to, or progressed within 6 months of, a rituximab-based regimen. Bendamustine has efficacy both as a single agent as well as in combination with other chemotherapeutics and immunotherapeutics. Here, we will discuss in the detail the molecular properties, clinical efficacy and safety profile of bendamustine.
引用
收藏
页码:1353 / 1365
页数:13
相关论文
共 40 条
  • [1] Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives
    Aivado, M
    Schulte, K
    Henze, L
    Burger, J
    Finke, J
    Haas, R
    [J]. SEMINARS IN ONCOLOGY, 2002, 29 (04) : 19 - 22
  • [2] [Anonymous], BLOOD
  • [3] [Anonymous], 2022, CA-CANCER J CLIN
  • [4] Bergmann MA, 2005, HAEMATOLOGICA, V90, P1357
  • [5] High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas
    Bremer, K
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (11) : 603 - 609
  • [6] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
    Byrd, JC
    Peterson, BL
    Morrison, VA
    Park, K
    Jacobson, R
    Hoke, E
    Vardiman, JW
    Rai, K
    Schiffer, CA
    Larson, RA
    [J]. BLOOD, 2003, 101 (01) : 6 - 14
  • [7] Cheson Bruce D, 2009, Clin Adv Hematol Oncol, V7, P743
  • [8] Cheson BD, 2009, BLOOD, V114, P1049
  • [9] Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel
    Cheson, Bruce D.
    Wendtner, Clemens-Martin
    Pieper, Angelika
    Dreyling, Martin
    Friedberg, Jonathan
    Hoelzer, Dieter
    Moreau, Philippe
    Gribben, John
    Knop, Stefan
    Montillo, Marco
    Rummel, Mathias
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01) : 21 - 27
  • [10] Eichhorst BF, 2008, BLOOD, V112, P385